middle.news
Emyria’s MDMA Therapy Shows Lasting PTSD Relief in Early Clinical Data
9:25am on Tuesday 4th of February, 2025 AEDT
•
Healthcare
Read Story
Emyria’s MDMA Therapy Shows Lasting PTSD Relief in Early Clinical Data
9:25am on Tuesday 4th of February, 2025 AEDT
Key Points
Average PTSD symptom scores dropped by 29.6 points at 3-month follow-up
Quality of life improved significantly with a 23.5-point increase in ReQoL scores
100% treatment completion rate among initial eight patients with severe PTSD
Mild and manageable side effects reported in one-quarter of patients
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Emyria (ASX:EMD)
OPEN ARTICLE